Biomarker & Intervention Discovery

Age-Related Hearing Loss (Presbycusis)

This page lists 6 recent clinical trials for Age-Related Hearing Loss (Presbycusis), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Sources are linked so you can check every claim.

Research Tracker Chronic Disease Interventions Age-Related Hearing Loss (Presbycusis)

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
—
Gap size
—
Primary barrier
—

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Age-Related Hearing Loss (Presbycusis): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss Recruiting
NCT07637981 Phase: 2 Started: 2026-05-13

Phase 2a: Multiple Ascending Dose (MAD) in male and female patients with hearing loss: The study will be conducted according to a randomised, placebo-controlled, double-blind design. A total of 24 patients, otherwise healthy, aged up to 75 years old, with mild to moderate hearing loss will be includ...

Efficacy and Safety of Liuwei Dihuang Pill Versus Placebo in Presbycusis With Shen (Kidney)-Yin Deficiency Completed
NCT05125081 Phase: 2 Started: 2022-01-25

The objective of this study is to examine the effects and safety of Liuwei Dihuang pill and placebo in presbycusis with Shen (kidney)-yin deficiency.

FX-322 in Adults With Age-Related Sensorineural Hearing Loss Completed
NCT04601909 Phase: 1 Started: 2020-09-17

This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with age-related sensorineural hearing loss.

Treating Hearing Loss to Improve Mood and Cognition in Older Adults Completed
NCT03321006 Phase: 4 Started: 2018-05-30

Age-related hearing loss (ARHL) is the third most common health condition affecting older adults after heart disease and arthritis and is the fifth leading cause of years lived with disability worldwide. Many hearing-impaired older adults avoid or withdraw from social contexts in which background no...

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss Completed
NCT01518920 Phase: 1 Started: 2011-12

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss Completed
NCT02345031 Phase: 2 Started: 2015-01

This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.

Agents Found By Disease-Level Search

Searched directly from “Age-Related Hearing Loss (Presbycusis)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 0-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."